CoChat

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

Open access
Johannsson, Gudmundur, Feldt-Rasmussen, Ulla, Håkonsson, Ida Holme, Biering, Henrik, Rodien, Patrice, Tahara, Shigeyuki, Toogood, Andrew, Rasmussen, Michael Højby, _, _, _, _, Biering, Henrik, Karges, Wolfram, Mann, Alexander, Christiansen, Jens Sandahl, Hansen, Troels Krarup, Andersen, Marianne, Feldt-Rasmussen, Ulla, Borresen, Sine, Rodien, Patrice, Borson-Chazot, Françoise, Kerlan, Véronique, Cariou, Bertrand, Verges, Bruno, Tahara, Shigeyuki, Matsuno, Akira, Takano, Koji, Tagami, Tetsuya, Takahashi, Yutaka, Takahashi, Toshikazu, Yamamoto, Masahiro, Johannsson, Gudmundur, Höybye, Charlotte, Erfurth, Eva-Marie, Drake, William, Higham, Claire, Murray, Robert, Toogood, Andrew, Brooke, Antonia · 2018 · European Journal of Endocrinology
Cited by 73

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin®. Local tolerability and treatment satisfaction were also assessed. Design: 26-week randomized, controlled phase 3 safety and tolerability trial in six countries (Nbib2382939). Methods: Male or female patients aged 18–79 years with adult GH deficiency (AGHD), treated with once-daily GH for ≥6 months, were randomized to once-weekly somapacitan (n = 61) or once-daily Norditropin (n = 31) administered subcutaneously by pen. Both treatments were dose titrated for 8 weeks to achieve insulin-like growth factor I (IGF-I) standard deviation score (SDS) levels within the normal range, and then administered at a fixed dose. Outcome measures were adverse events (AEs), including injection site reactions; occurrence of anti-somapacitan/anti-GH antibodies and change in treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). Results: Mean IGF-I SDS remained between 0 and 2 SDS throughout the trial in both groups. AEs were mostly mild or moderate and transient in nature. The most common AEs were nasopharyngitis, headache and fatigue in both groups. More than 1500 somapacitan injections were administered and no clinically significant injection site reactions were reported. No anti-somapacitan or anti-GH antibodies were detected. The TSQM-9 score for convenience increased significantly more with somapacitan vs Norditropin (P = 0.0171). Conclusions: In this 26-week trial in patients with AGHD, somapacitan was well tolerated and no safety issues were identified. Once-weekly somapacitan was reported to be more convenient than once-daily Norditropin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-17-1073

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 73

Metadata

Authors
Johannsson, G., Feldt-Rasmussen, U., Håkonsson, I. H., Biering, H., Rodien, P., Tahara, S., Toogood, A., Rasmussen, M. H., _, _., _, _., Biering, H., Karges, W., Mann, A., Christiansen, J. S., Hansen, T. K., Andersen, M., Feldt-Rasmussen, U., Borresen, S., Rodien, P., Borson-Chazot, F., Kerlan, V., Cariou, B., Verges, B., Tahara, S., Matsuno, A., Takano, K., Tagami, T., Takahashi, Y., Takahashi, T., Yamamoto, M., Johannsson, G., Höybye, C., Erfurth, E.-M., Drake, W., Higham, C., Murray, R., Toogood, A., & Brooke, A.
Venue
European Journal of Endocrinology
Published
2018-05
Volume
178
Issue
5
Pages
491-499
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2792828483
Cited by
73
References
5
FWCI
3.58
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. https://app.cochat.ai/papers/10.1530/eje-17-1073
The paper
Johannsson, G., Feldt-Rasmussen, U., Håkonsson, I. H., Biering, H., Rodien, P., Tahara, S., Toogood, A., Rasmussen, M. H., _, _., _, _., Biering, H., Karges, W., Mann, A., Christiansen, J. S., Hansen, T. K., Andersen, M., Feldt-Rasmussen, U., Borresen, S., Rodien, P., . . . Brooke, A. (2018). Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. European Journal of Endocrinology. https://doi.org/10.1530/eje-17-1073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.